CannTrust Holdings has received notice from Health Canada that the Company’s licenses for its Fenwick Perpetual Harvest Facility have been reinstated.
"CannTrust has been working in collaboration with Health Canada for many months to identify and address the Company’s regulatory deficiencies," the team with the company explains. "On February 14, 2020, the Company announced that it had completed its remediation activities at the Fenwick facility, and that documentation in support of license reinstatement had been submitted to Health Canada."
"CannTrust will immediately recommence operations at the Fenwick facility, which is located in the Niagara region. At this time, the Company cannot provide an exact timeframe for when its products will be available in the market, which is dependent upon receiving a response from Health Canada to CannTrust’s licence reinstatement submission with respect to its Vaughan manufacturing facility, which was submitted to Health Canada more recently, on April 24, 2020. The decision to reinstate the Company’s licenses at its Vaughan facility is both independent of the Fenwick facility’s licence reinstatement and at the discretion of Health Canada."
As previously announced, CannTrust is currently under CCAA protection to facilitate the Company’s efforts to resolve its civil litigation exposures and complete its review of strategic alternatives. Those efforts are ongoing, and the Company is unable to predict either their timing or their outcome. In the meantime, CannTrust remains without meaningful revenues and has terminated or laid-off a significant portion of its workforce. The Company plans to begin operations following today’s announcement as an important first step towards rebuilding stakeholder trust and delivering high-quality, innovative products to its patients and customers.
For more information:
CannTrust
canntrust.ca